Validated high-conviction buyer — this insider’s opportunistic purchases fall in a cohort whose buys have historically preceded above-benchmark moves. How we measure this ↗
CEO James Caruso buys 8,680 shares as CLRB stock trades 78% below 52-week high amid ongoing losses.
CEO James Caruso is adding materially to his stake, acquiring shares that represent three-quarters of his existing holdings at a time when Cellectar remains unprofitable with significant quarterly operating losses. The stock is trading far below its 52-week high, creating a backdrop where an insider buy might suggest conviction—but the insider's track record offers caution: his prior open-market purchase at this company saw the stock decline in the following month before eventually recovering, a conflicting pattern that offers no clear signal about his timing ability. Cellectar's financial fundamentals remain challenged, with the company burning cash and posting substantial losses, leaving little room to interpret this purchase as a vote of confidence in near-term turnaround. This is only Caruso's second open-market purchase in the 36-month window, and the stock's price action since his last buy—early losses followed by longer-term gains—suggests even prior conviction did not translate into reliable foresight. Without independent positive catalysts or financial improvement, this buy alone does not warrant investor optimism.
CEO James Caruso buys 10,000 shares at $4.99; stock down -94.7% from $90.60 high; cluster buy pattern emerges with 2 other insiders in 14 days.
CEO James Caruso purchased 10,000 shares (10.0K shares) at $4.99 on 2025-07-02, increasing his holdings by 610.5%, while the stock trades at $4.80—down -94.7% from its 52-week high of $90.60 and -42.4% over the past 30 days. The company reported negative full-year net income of $-6,604,029.00, indicating ongoing unprofitability. This buy occurs as part of a cluster pattern with 2 other insiders purchasing within the past 14 days, suggesting coordinated or reactive accumulation during a period of sharp price deterioration. The timing and magnitude of the purchase relative to the stock's collapse and the company's negative earnings warrant investor scrutiny into whether this reflects management's assessment of undervaluation or signals additional business headwinds not yet reflected in market pricing.
